Association Between Lactate Dehydrogenase Levels to the Response of Non-Hodgkin Lymphoma in Elderly Patients Who Treated with First-Line Chemotherapy in Sanglah General Hospital

Overview

Journal Open Access Maced J Med Sci

Specialty General Medicine

Date 2019 Aug 14

PMID 31406541

Citations 1

Authors

Cokorda Agung Wahyu Purnamasidhi

Ketut Suega

I Made Bakta

Affiliations

Soon will be listed here.

Abstract

Background: Non-Hodgkin Lymphoma (NHL) is a malignant haematological disease originates in the lymphocytes, caused by an abnormality in lymphocytes development which forms a tumour and may become cancer. Chemotherapy is the main treatment modality for aggressive lymphoma, but only a few patients achieve remission. Several factors such as age, clinical stadium, number of extranodal regions, and Lactate Dehydrogenase (LDH) level played a role in determining response to chemotherapy.

Aim: To measure the association between LDH levels to prognosis of NHL in elderly patients who treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in Sanglah General Hospital.

Methods: This study used a retrospective descriptive study on elderly NHL patients in Sanglah General Hospital from January until December 2014. The evaluation was measured using the IPI score to determine the prognosis of patients. Demographic data, the stadium, extranodal region, LDH level, and response to chemotherapy were recorded.

Results: Twenty-five patients were included in the study. The age ranged was between 61-76 years old (Mean 65,68 ± 4,7 years; Median 65 years). The number of male patients was 19 (76%). Diffuse Large B-Cell Lymphoma (DLBCL) is the most common histopathological structure observed on the patients (68%). LDH levels were normal in 51.6% of the patients and considered high in the rests (48.4%). Results of the chemotherapy were a good response in 72.2%. Compared to the patients who showed complete response to chemotherapy, patients with no response (partial response and progression) had significantly higher levels of LDH (OR: 13,1; 95% CI: 1,36-126,30; p = 0,001).

Conclusion: Non-Hodgkin Lymphoma in elderly patients with no response to chemotherapy had significantly higher levels of LDH than patients with complete response.

Citing Articles

Clinicopathologic study of mantle cell lymphoma with epstein-barr virus infection: A case series and literature review.

Li X, Zhou F, Li S, Wang Y, Fan J, Liang X Front Oncol. 2022; 12:933964.

PMID: 35992854 PMC: 9386618. DOI: 10.3389/fonc.2022.933964.

References

Jurisic V, Konjevic G, Banicevic B, Duricic B, SPUZIC I . Different alterations in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkin's and non-Hodgkin's lymphomas. Eur J Haematol. 2000; 64(4):259-66. DOI: 10.1034/j.1600-0609.2000.90117.x. View

Schmoll H, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C . European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004; 15(9):1377-99. DOI: 10.1093/annonc/mdh301. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Tilly H, Dreyling M . Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4:110-2. DOI: 10.1093/annonc/mdp145. View

Gonzalez-Billalabeitia E, Hitt R, Fernandez J, Conde E, Martinez-Tello F, Enriquez de Salamanca R . Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma. Clin Transl Oncol. 2009; 11(7):479-83. DOI: 10.1007/s12094-009-0388-9. View

Le A, Cooper C, Gouw A, Dinavahi R, Maitra A, Deck L . Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010; 107(5):2037-42. PMC: 2836706. DOI: 10.1073/pnas.0914433107. View

Hong J, Park S, Park J, Kim H, Kim K, Ahn J . Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 2011; 52(10):1904-12. DOI: 10.3109/10428194.2011.588761. View

El-Sharkawi D, Basu S, Ocampo C, Qian W, DSa S, Hoskin P . Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin,.... Leuk Lymphoma. 2012; 53(10):1949-52. DOI: 10.3109/10428194.2012.679360. View

Augoff K, Hryniewicz-Jankowska A, Tabola R . Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett. 2014; 358(1):1-7. DOI: 10.1016/j.canlet.2014.12.035. View

10.

Bacci G, Avella M, McDonald D, Toni A, Orlandi M, Campanacci M . Serum lactate dehydrogenase (LDH) as a tumor marker in Ewing's sarcoma. Tumori. 1988; 74(6):649-55. DOI: 10.1177/030089168807400606. View

11.

Ferraris A, Giuntini P, Gaetani G . Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979; 54(4):928-32. View

12.

Schneider R, Seibert K, Passe S, Little C, Gee T, Lee 3rd B . Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer. 1980; 46(1):139-43. DOI: 10.1002/1097-0142(19800701)46:1<139::aid-cncr2820460122>3.0.co;2-8. View

13.

. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94. DOI: 10.1056/NEJM199309303291402. View